ICGA-A and CRA, bioactive compounds from Taraxacum officinale, exhibit significant antitumor activity in TNBC by targeting the FAK/PI3K/AKT/mTOR pathway, a critical regulator of cancer progression. This evidence concerns the gene AKT1 and cancer.